Independent register of U.S. FDA drug recalls · updated Oct 11, 2026
RxRecalls Get alerts

FDA Drug Recalls

18,003 recalls, newest first

Class III · Low risk

Tivicay (dolutegravir)

Labeling: incorrect or missing lot and/or expiration date. An incorrect expiration date was printed on the product labeling with an expiration date of January 2027, whereas the correct expiration date is September 2026.

Terminated Labeling / mix-up GlaxoSmithKline LLC NDC 49702-228-13 D-0896-2022
Class II · Moderate risk

Zonisamide Capsules USP

CGMP Deviations: Gaps in the quality system in the Quality Control microbiology laboratory.

Terminated Microbial contamination Direct Rx NDC 61919-775-90 D-0888-2022
Class II · Moderate risk

Alcohol Antiseptic 80%

CGMP Deviations: FDA analysis found product to contain acetaldehyde and acetal above specification limits.

Ongoing cGMP deviation A.P. Nonweiler D-1142-2022
Class I · High risk

Anagrelide Capsules USP

Failed Dissolution Specifications- Low Out-Of-Specification results obtained during stability testing.

Terminated Dissolution failure Teva Pharmaceuticals USA Inc NDC 0172-5241-60 D-0992-2022
Class II · Moderate risk

Myers Cocktail

Lack of assurance of sterility.

Completed Sterility / contamination Olympia Compounding Pharmacy dba Olympia Pharmacy NDC 73198-0088-10 D-0938-2022
Class II · Moderate risk

Micc

Lack of assurance of sterility.

Completed Sterility / contamination Olympia Compounding Pharmacy dba Olympia Pharmacy NDC 73198-0052-10 D-0937-2022

Recalls by year